Novartis' Rhapsido meets primary goal in Phase III skin disorder study
- Posted on June 15, 2026
- By Bing News
- 0 Views
- 1 min read
Novartis' Rhapsido meets primary goal in Phase III skin disorder study
Novartis NVS announced positive results from the RemIND study on Rhapsido (remibrutinib) for chronic inducible urticaria (CIndU), a chronic skin condition, at the European Academy of Allergy and Clinical Immunology (“EAACI”) Congress. Results showed Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients versus placebo, with favorable safety profile and without any observed liver safety...
